Pattern-recognition receptors and gastric cancer

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Castaño Rodríguez, Natalia ^a   Kaakoush, Nadeem O ^a   Mitchell, Hazel M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Genetic polymorphism; Helicobacter pylori; Inflammation; NOD like receptors; Pattern recognition receptors; Stomach neoplasm; Therapeutics; Toll like receptors

Indexed keywords

EID: 84905639538     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00336     Document Type: Review

References (275)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer (2013).
2. Hamilton SR, Aaltonen LA, editors. Tumours of the Digestive System. Lyon: IARC Press (2000).
3. Mccoll KE. Cancer of the gastric cardia. Best Pract Res Clin Gastroenterol (2006) 20:687-96. doi: 10.1016/j.bpg.2006.03.005
4. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer (2014) 50:1330-44. doi:10.1016/j.ejca.2014.01.029
5. Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control (2011) 22:375-87. doi:10.1007/s10552-010-9707-2
6. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut (2007) 56:918-25. doi:10.1136/gut.2006.114504
7. Correa P. A human model of gastric carcinogenesis. Cancer Res (1988) 48:3554-60.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57-70. doi:10.1016/S0092-8674(00)81683-9
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
10. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med (1995) 333:32-41. doi:10.1056/NEJM199507063330107
11. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res (1992) 52:6735-40.
12. Li H, Stoicov C, Cai X, Wang TC, Houghton J. Helicobacter and gastric cancer disease mechanisms: host response and disease susceptibility. Curr Gastroenterol Rep (2003) 5:459-67. doi:10.1007/s11894-003-0034-6
13. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. Prog Mol Biol Transl Sci (2013) 116:337-59. doi:10.1016/B978-0-12-394311-8.00015-7
14. Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev (2006) 19:449-90. doi:10.1128/CMR.00054-05
15. Costa NR, Mendes N, Marcos NT, Reis CA, Caffrey T, Hollingsworth MA, et al. Relevance of MUC1 mucin variable number of tandem repeats polymorphism in H. pylori adhesion to gastric epithelial cells. World J Gastroenterol (2008) 14:1411-4. doi:10.3748/wjg.14.1411
16. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol (2006) 1:63-96. doi:10.1146/annurev.pathol.1.110304.100125
17. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med (2002) 347:1175-86. doi:10.1056/NEJMra020542
18. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev (2010) 23:713-39. doi:10.1128/CMR.00011-10
19. El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, Mccoll KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology (1995) 109:681-91. doi:10.1016/0016-5085(95)90374-7
20. Kivi M, Tindberg Y, Sorberg M, Casswall TH, Befrits R, Hellstrom PM, et al. Concordance of Helicobacter pylori strains within families. J Clin Microbiol (2003) 41:5604-8. doi:10.1128/JCM.41.12.5604-5608.2003
21. Konno M, Fujii N, Yokota S, Sato K, Takahashi M, Mino E, et al. Five-year follow-up study of mother-to-child transmission of Helicobacter pylori infection detected by a random amplified polymorphic DNA fingerprinting method. J Clin Microbiol (2005) 43:2246-50. doi:10.1128/JCM.43.5.2246-2250.2005
22. Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of Helicobacter pylori. Gastroenterology (2006) 130:65-72;quiz211. doi:10.1053/j.gastro.2005.11.004
23. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology (2009) 136:1863-73. doi:10.1053/j.gastro.2009.01.073
24. Neiger R, Simpson KW. Helicobacter infection in dogs and cats: facts and fiction. J Vet Intern Med (2000) 14:125-33. doi:10.1111/j.1939-1676.2000.tb02225.x
25. Simpson KW, Strauss-Ayali D, Straubinger RK, Scanziani E, Mcdonough PL, Straubinger AF, et al. Helicobacter pylori infection in the cat: evaluation of gastric colonization, inflammation and function. Helicobacter (2001) 6:1-14. doi:10.1046/j.1523-5378.2001.00010.x
26. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A (2006) 103:732-7. doi:10.1073/pnas.0506655103
27. Bauerfeind P, Garner R, Dunn BE, Mobley HL. Synthesis and activity of Helicobacter pylori urease and catalase at low pH. Gut (1997) 40:25-30.
28. Marshall BJ, Barrett LJ, Prakash C, Mccallum RW, Guerrant RL. Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology (1990) 99:697-702.
29. Merrell DS, Goodrich ML, Otto G, Tompkins LS, Falkow S. pH-regulated gene expression of the gastric pathogen Helicobacter pylori. Infect Immun (2003) 71:3529-39. doi:10.1128/IAI.71.6.3529-3539.2003
30. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science (1998) 279:373-7. doi:10.1126/science.279.5349.373
31. Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science (2002) 297:573-8. doi:10.1126/science.1069076
32. Putsep K, Branden CI, Boman HG, Normark S. Antibacterial peptide from H. pylori. Nature (1999) 398:671-2. doi:10.1038/19439
33. Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science (2003) 301:1099-102. doi:10.1126/science.1086871
34. Sundrud MS, Torres VJ, Unutmaz D, Cover TL. Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc Natl Acad Sci U S A (2004) 101:7727-32. doi:10.1073/pnas.0401528101
35. Supajatura V, Ushio H, Wada A, Yahiro K, Okumura K, Ogawa H, et al. Cutting edge: VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines. J Immunol (2002) 168:2603-7. doi:10.4049/jimmunol.168.6.2603
36. Torres VJ, Vancompernolle SE, Sundrud MS, Unutmaz D, Cover TL. Helicobacter pylori vacuolating cytotoxin inhibits activation-induced proliferation of human T and B lymphocyte subsets. J Immunol (2007) 179:5433-40. doi:10.4049/jimmunol.179.8.5433
37. Schmees C, Prinz C, Treptau T, Rad R, Hengst L, Voland P, et al. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology (2007) 132:1820-33. doi:10.1053/j.gastro.2007.02.031
38. Gobert AP, Mcgee DJ, Akhtar M, Mendz GL, Newton JC, Cheng Y, et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc Natl Acad Sci U S A (2001) 98:13844-9. doi:10.1073/pnas.241443798
39. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A (1996) 93:14648-53. doi:10.1073/pnas.93.25.14648
40. Akopyants NS, Clifton SW, Kersulyte D, Crabtree JE, Youree BE, Reece CA, et al. Analyses of the cag pathogenicity island of Helicobacter pylori. Mol Microbiol (1998) 28:37-53. doi:10.1046/j.1365-2958.1998.00770.x
41. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A (1993) 90:5791-5. doi:10.1073/pnas.90.12.5791
42. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 388:539-47. doi:10.1038/41483
43. Odenbreit S, Puls J, Sedlmaier B, Gerland E, Fischer W, Haas R. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science (2000) 287:1497-500. doi:10.1126/science.287.5457.1497
44. Posselt G, Backert S, Wessler S. The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal (2013) 11:77. doi:10.1186/1478-811X-11-77
45. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science (2002) 295:683-6. doi:10.1126/science.1067147
46. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene (2007) 26:4617-26. doi:10.1038/sj.onc.1210251
47. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci U S A (1999) 96:14559-64. doi:10.1073/pnas.96.25.14559
48. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res (1995) 55:2111-5.
49. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 94:1680-7. doi:10.1093/jnci/94.22.1680
50. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 345:1525-8. doi:10.1016/S0140-6736(95)91084-0
51. Plummer M, Van Doorn LJ, Franceschi S, Kleter B, Canzian F, Vivas J, et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst (2007) 99:1328-34. doi:10.1093/jnci/djm120
52. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med (1991) 325:1132-6. doi:10.1056/NEJM199110173251604
53. Nomura AM, Lee J, Stemmermann GN, Nomura RY, Perez-Perez GI, Blaser MJ. Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J Infect Dis (2002) 186:1138-44. doi:10.1086/343808
54. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 325:1127-31. doi:10.1056/NEJM199110173251603
55. Pinto-Santini D, Salama NR. The biology of Helicobacter pylori infection, a major risk factor for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2005) 14:1853-8. doi:10.1158/1055-9965.EPI-04-0784
56. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med (2001) 345:784-9. doi:10.1056/NEJMoa001999
57. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut (1997) 40:297-301.
58. Seoane A, Bessa X, Balleste B, O'Callaghan E, Panades A, Alameda F, et al. [Helicobacter pylori and gastric cancer: relationship with histological subtype and tumor location]. Gastroenterol Hepatol (2005) 28:60-4. doi:10.1157/13070701
59. Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci (2010) 55:3124-31. doi:10.1007/s10620-010-1351-x
60. Ekstrom AM, Held M, Hansson LE, Engstrand L, Nyren O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology (2001) 121:784-91. doi:10.1053/gast.2001.27999
61. Siman JH, Engstrand L, Berglund G, Forsgren A, Floren CH. Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol (2007) 42:933-40. doi:10.1080/00365520601173863
62. Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol (2010) 176:1564-76. doi:10.2353/ajpath.2010.090786
63. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol (2007) 28:519-24. doi:10.1016/j.it.2007.09.004
64. Denardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 29:309-16. doi:10.1007/s10555-010-9223-6
65. Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 222:145-54. doi:10.1111/j.1600-065X.2008.00600.x
66. Wu MS, Chen CJ, Lin JT. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev (2005) 14:1878-82. doi:10.1158/1055-9965.EPI-04-0792
67. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420:860-7. doi:10.1038/nature01322
68. Tsuji S, Kawai N, Tsujii M, Kawano S, Hori M. Review article: inflammation-related promotion of gastrointestinal carcinogenesis - a perigenetic pathway. Aliment Pharmacol Ther (2003) 18(Suppl 1):82-9. doi:10.1046/j.1365-2036.18.s1.22.x
69. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res (1990) 50:4731-6.
70. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res (2004) 10:201-22. doi:10.1179/096805104225006129
71. Helmby H, Grencis RK. Interleukin 1 plays a major role in the development of Th2-mediated immunity. Eur J Immunol (2004) 34:3674-81. doi:10.1002/eji.200425452
72. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 123:1793-803. doi:10.1053/gast.2002.37043
73. Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 15:1674-87. doi:10.1158/1055-9965.EPI-06-0189
74. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol (2010) 25:1604-17. doi:10.1111/j.1440-1746.2010.06428.x
75. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol (2011) 166:1-15. doi:10.1111/j.1365-2249.2011.04440.x
76. Hartland S, Newton JL, Griffin SM, Donaldson PT. A functional polymorphism in the interleukin-1 receptor-1 gene is associated with increased risk of Helicobacter pylori infection but not with gastric cancer. Dig Dis Sci (2004) 49:1545-50. doi:10.1023/B:DDAS.0000042262.14969.2d
77. Peleteiro B, Lunet N, Carrilho C, Duraes C, Machado JC, La Vecchia C, et al. Association between cytokine gene polymorphisms and gastric precancerous lesions: systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 19:762-76. doi:10.1158/1055-9965.EPI-09-0917
78. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systematic review and meta-analyses. Am J Epidemiol (2011) 173:259-70. doi:10.1093/aje/kwq370
79. Yuzhalin A. The role of interleukin DNA polymorphisms in gastric cancer. Hum Immunol (2011) 72:1128-36. doi:10.1016/j.humimm.2011.08.003
80. Wang J, He W, Liu J, Nong L, Wei Y, Yang F. Association of IL-6 polymorphisms with gastric cancer risk: evidences from a meta-analysis. Cytokine (2012) 59:176-83. doi:10.1016/j.cyto.2012.03.032
81. Yin YW, Hu AM, Sun QQ, Liu HL, Wang Q, Zeng YH, et al. Association between interleukin-6 gene -174 G/C polymorphism and the risk of coronary heart disease: a meta-analysis of 20 studies including 9619 cases and 10,919 controls. Gene (2012) 503:25-30. doi:10.1016/j.gene.2012.04.075
82. Da Costa DM, Neves-Filho EH, Alves MK, Rabenhorst SH. Interleukin polymorphisms and differential methylation status in gastric cancer: an association with Helicobacter pylori infection. Epigenomics (2013) 5:167-75. doi:10.2217/epi.13.7
83. Xue H, Liu J, Lin B, Wang Z, Sun J, Huang G. A meta-analysis of interleukin-8 -251 promoter polymorphism associated with gastric cancer risk. PLoS One (2012) 7:e28083. doi:10.1371/journal.pone.0028083
84. Ni P, Xu H, Xue H, Lin B, Lu Y. A meta-analysis of interleukin-10-1082 promoter polymorphism associated with gastric cancer risk. DNA Cell Biol (2012) 31:582-91. doi:10.1089/dna.2011.1440
85. Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS (2013) 17:200-14. doi:10.1089/omi.2012.0089
86. Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX, et al. Interleukin10 -592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci (2010) 55:1525-32. doi:10.1007/s10620-009-0922-1
87. Yuzhalin AE, Kutikhin AG. Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors (2012) 30:176-91. doi:10.3109/08977194.2012.678843
88. Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol (2009) 24:1119-22. doi:10.1111/j.1440-1746.2009.05791.x
89. Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer (2008) 98:1443-51. doi:10.1038/sj.bjc.6604277
90. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol (2011) 11:9-20. doi:10.1038/nri2891
91. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol (2011) 29:707-35. doi:10.1146/annurev-immunol-031210-101405
92. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol (2010) 11:997-1004. doi:10.1038/ni.1932
93. Schroder K, Tschopp J. The inflammasomes. Cell (2010) 140:821-32. doi:10.1016/j.cell.2010.01.040
94. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 27:229-65. doi:10.1146/annurev.immunol.021908.132715
95. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 21:335-76. doi:10.1146/annurev.immunol.21.120601.141126
96. Basak C, Pathak SK, Bhattacharyya A, Mandal D, Pathak S, Kundu M. NF-kappaB- and C/EBPbeta-driven interleukin-1beta gene expression and PAK1-mediated caspase-1 activation play essential roles in interleukin-1beta release from Helicobacter pylori lipopolysaccharide-stimulated macrophages. J Biol Chem (2005) 280:4279-88. doi:10.1074/jbc.M412820200
97. Kawahara T, Teshima S, Oka A, Sugiyama T, Kishi K, Rokutan K. Type I Helicobacter pylori lipopolysaccharide stimulates toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells. Infect Immun (2001) 69:4382-9. doi:10.1128/IAI.69.7.4382-4389.2001
98. Maeda S, Akanuma M, Mitsuno Y, Hirata Y, Ogura K, Yoshida H, et al. Distinct mechanism of Helicobacter pylori-mediated NF-kappa B activation between gastric cancer cells and monocytic cells. J Biol Chem (2001) 276:44856-64. doi:10.1074/jbc.M105381200
99. Su B, Ceponis PJ, Lebel S, Huynh H, Sherman PM. Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun (2003) 71:3496-502. doi:10.1128/IAI.71.6.3496-3502.2003
100. Thomas CJ, Kapoor M, Sharma S, Bausinger H, Zyilan U, Lipsker D, et al. Evidence of a trimolecular complex involving LPS, LPS binding protein and soluble CD14 as an effector of LPS response. FEBS Lett (2002) 531:184-8. doi:10.1016/S0014-5793(02)03499-3
101. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4:499-511. doi:10.1038/nri1391
102. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 167:5887-94. doi:10.4049/jimmunol.167.10.5887
103. Basu S, Pathak SK, Chatterjee G, Pathak S, Basu J, Kundu M. Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells. J Biol Chem (2008) 283:32369-76. doi:10.1074/jbc.M805053200
104. Chochi K, Ichikura T, Kinoshita M, Majima T, Shinomiya N, Tsujimoto H, et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res (2008) 14:2909-17. doi:10.1158/1078-0432.CCR-07-4467
105. Ishihara S, Rumi MA, Kadowaki Y, Ortega-Cava CF, Yuki T, Yoshino N, et al. Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis. J Immunol (2004) 173:1406-16. doi:10.4049/jimmunol.173.2.1406
106. Cunningham MD, Seachord C, Ratcliffe K, Bainbridge B, Aruffo A, Darveau RP. Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14. Infect Immun (1996) 64:3601-8.
107. Smith MF Jr, Mitchell A, Li G, Ding S, Fitzmaurice AM, Ryan K, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem (2003) 278:32552-60. doi:10.1074/jbc.M305536200
108. Chang YJ, Wu MS, Lin JT, Sheu BS, Muta T, Inoue H, et al. Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. Mol Pharmacol (2004) 66:1465-77. doi:10.1124/mol.104.005199
109. Gobert AP, Bambou JC, Werts C, Balloy V, Chignard M, Moran AP, et al. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem (2004) 279:245-50. doi:10.1074/jbc.M307858200
110. Lepper PM, Triantafilou M, Schumann C, Schneider EM, Triantafilou K. Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4. Cell Microbiol (2005) 7:519-28. doi:10.1111/j.1462-5822.2005.00482.x
111. Mandell L, Moran AP, Cocchiarella A, Houghton J, Taylor N, Fox JG, et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun (2004) 72:6446-54. doi:10.1128/IAI.72.11.6446-6454.2004
112. Rad R, Ballhorn W, Voland P, Eisenacher K, Mages J, Rad L, et al. Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology (2009) 136:2247-57. doi:10.1053/j.gastro.2009.02.066
113. Chaouche-Drider N, Kaparakis M, Karrar A, Fernandez MI, Carneiro LA, Viala J, et al. A commensal Helicobacter sp. of the rodent intestinal flora activates TLR2 and NOD1 responses in epithelial cells. PLoS One (2009) 4:e5396. doi:10.1371/journal.pone.0005396
114. Sayi A, Kohler E, Toller IM, Flavell RA, Muller W, Roers A, et al. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol (2011) 186:878-90. doi:10.4049/jimmunol.1002269
115. Smith SM, Moran AP, Duggan SP, Ahmed SE, Mohamed AS, Windle HJ, et al. Tribbles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter pylori lipopolysaccharide. J Immunol (2011) 186:2462-71. doi:10.4049/jimmunol.1000864
116. Obonyo M, Sabet M, Cole SP, Ebmeyer J, Uematsu S, Akira S, et al. Deficiencies of myeloid differentiation factor 88, Toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori. Infect Immun (2007) 75:2408-14. doi:10.1128/IAI.01794-06
117. Takenaka R, Yokota K, Ayada K, Mizuno M, Zhao Y, Fujinami Y, et al. Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the Toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiology (2004) 150:3913-22. doi:10.1099/mic.0.27527-0
118. Yokota S, Okabayashi T, Rehli M, Fujii N, Amano K. Helicobacter pylori lipopolysaccharides upregulate toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infect Immun (2010) 78:468-76. doi:10.1128/IAI.00903-09
119. Otani K, Tanigawa T, Watanabe T, Nadatani Y, Sogawa M, Yamagami H, et al. Toll-like receptor 9 signaling has anti-inflammatory effects on the early phase of Helicobacter pylori-induced gastritis. Biochem Biophys Res Commun (2012) 426:342-9. doi:10.1016/j.bbrc.2012.08.080
120. Lagunes-Servin H, Torres J, Maldonado-Bernal C, Perez-Rodriguez M, Huerta-Yepez S, Madrazo De La Garza A, et al. Toll-like receptors and cytokines are upregulated during Helicobacter pylori infection in children. Helicobacter (2013) 18:423-32. doi:10.1111/hel.12067
121. Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM Jr. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis (2004) 189:1914-20. doi:10.1086/386289
122. Kumar Pachathundikandi S, Brandt S, Madassery J, Backert S. Induction of TLR-2 and TLR-5 expression by Helicobacter pylori switches cagPAI-dependent signalling leading to the secretion of IL-8 and TNF-alpha. PLoS One (2011) 6:e19614. doi:10.1371/journal.pone.0019614
123. Andersen-Nissen E, Smith KD, Strobe KL, Barrett SL, Cookson BT, Logan SM, et al. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci U S A (2005) 102:9247-52. doi:10.1073/pnas.0502040102
124. Muotiala A, Helander IM, Pyhala L, Kosunen TU, Moran AP. Low biological activity of Helicobacter pylori lipopolysaccharide. Infect Immun (1992) 60:1714-6.
125. Moran AP, Lindner B, Walsh EJ. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides. J Bacteriol (1997) 179:6453-63.
126. Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol (2005) 295:179-85. doi:10.1016/j.ijmm.2005.02.009
127. Pimentel-Nunes P, Afonso L, Lopes P, Roncon-Albuquerque R Jr, Goncalves N, Henrique R, et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res (2011) 17:677-83. doi:10.1007/s12253-011-9368-9
128. Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque R Jr, et al. Helicobacter pylori induces increased expression of Toll-like receptors and decreased Toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis. Helicobacter (2013) 18:22-32. doi:10.1111/hel.12008
129. Fernandez-Garcia B, Eiro N, Gonzalez-Reyes S, Gonzalez L, Aguirre A, Gonzalez LO, et al. Clinical significance of toll-like receptor 3, 4, and 9 in gastric cancer. J Immunother (2014) 37:77-83. doi:10.1097/CJI.0000000000000016
130. Yakut M, Ormeci N, Erdal H, Keskin O, Karayel Z, Tutkak H, et al. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status. Clin Res Hepatol Gastroenterol (2013) 37:302-11. doi:10.1016/j.clinre.2012.09.013
131. Song EJ, Kang MJ, Kim YS, Kim SM, Lee SE, Kim CH, et al. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med (2011) 28:115-9. doi:10.3892/ijmm.2011.656
132. Tye H, Kennedy CL, Najdovska M, Mcleod L, Mccormack W, Hughes N, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell (2012) 22:466-78. doi:10.1016/j.ccr.2012.08.010
133. Li K, Dan Z, Hu X, Gesang L, Ze Y, Bianba Z. CD14 regulates gastric cancer cell epithelial mesenchymal transition and invasion in vitro. Oncol Rep (2013) 30:2725-32. doi:10.3892/or.2013.2733
134. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett (2010) 295:7-16. doi:10.1016/j.canlet.2010.03.015
135. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell (2006) 10:175-6. doi:10.1016/j.ccr.2006.08.015
136. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res (2007) 67:10823-30. doi:10.1158/0008-5472.CAN-07-0783
137. Park JH, Kim TY, Jong HS, Chun YS, Park JW, Lee CT, et al. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin Cancer Res (2003) 9:433-40.
138. Yuan X, Zhou Y, Wang W, Li J, Xie G, Zhao Y, et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis (2013) 4:e794. doi:10.1038/cddis.2013.334
139. Kutikhin AG. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol (2011) 72:193-206. doi:10.1016/j.humimm.2010.11.003
140. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem (2002) 277:15028-34. doi:10.1074/jbc.M200497200
141. Guillot L, Balloy V, Mccormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol (2002) 168:5989-92. doi:10.4049/jimmunol.168.12.5989
142. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol (2002) 168:5233-9. doi:10.4049/jimmunol.168.10.5233
143. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol (2001) 167:2887-94. doi:10.4049/jimmunol.167.5.2887
144. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med (2002) 195:99-111. doi:10.1084/jem.20001858
145. Vabulas RM, Ahmad-Nejad P, Da Costa C, Miethke T, Kirschning CJ, Hacker H, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem (2001) 276:31332-9. doi:10.1074/jbc.M103217200
146. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol (2004) 4:675-87. doi:10.1038/nri1434
147. Kim CW, Choi SH, Chung EJ, Lee MJ, Byun EK, Ryu MH, et al. Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology (1999) 67:123-8. doi:10.1159/000028061
148. Takahashi A, Kono K, Amemiya H, Iizuka H, Fujii H, Matsumoto Y. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin Cancer Res (2001) 7:74-80.
149. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 61:765-72. doi:10.1002/ijc.2910610605
150. Healy CG, Simons JW, Carducci MA, Deweese TL, Bartkowski M, Tong KP, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry (1998) 32: doi:10.1002/(SICI)1097-0320(19980601)32:2109::AID-CYTO63.0.CO;2-G
151. Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Andersson B, et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res (1996) 2:1825-8.
152. Schmielau J, Nalesnik MA, Finn OJ. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res (2001) 7:933s-9s.
153. Wu Y, Zhao Q, Peng C, Sun L, Li XF, Kuang DM. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol (2011) 225:438-47. doi:10.1002/path.2947
154. Yang CA, Scheibenbogen C, Bauer S, Kleinle C, Wex T, Bornschein J, et al. A frequent Toll-like receptor 1 gene polymorphism affects NK- and T-cell IFN-gamma production and is associated with Helicobacter pylori-induced gastric disease. Helicobacter (2013) 18:13-21. doi:10.1111/hel.12001
155. Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. PLoS One (2013) 8:e60327. doi:10.1371/journal.pone.0060327
156. Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M, et al. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci (2007) 98:1790-4. doi:10.1111/j.1349-7006.2007.00590.x
157. de Oliveira JG, Rossi AF, Nizato DM, Miyasaki K, Silva AE. Profiles of gene polymorphisms in cytokines and Toll-like receptors with higher risk for gastric cancer. Dig Dis Sci (2013) 58:978-88. doi:10.1007/s10620-012-2460-5
158. Zeng HM, Pan KF, Zhang Y, Zhang L, Ma JL, Zhou T, et al. Genetic variants of toll-like receptor 2 and 5, helicobacter pylori infection, and risk of gastric cancer and its precursors in a chinese population. Cancer Epidemiol Biomarkers Prev (2011) 20:2594-602. doi:10.1158/1055-9965.EPI-11-0702
159. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2007) 132:905-12. doi:10.1053/j.gastro.2006.12.026
160. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol (2008) 154:360-4. doi:10.1111/j.1365-2249.2008.03776.x
161. Huang L, Yuan K, Liu J, Ren X, Dong X, Tian W, et al. Polymorphisms of the TLR4 gene and risk of gastric cancer. Gene (2014) 537:46-50. doi:10.1016/j.gene.2013.12.030
162. Kim J, Cho YA, Choi IJ, Lee YS, Kim SY, Hwang JA, et al. Effects of polymorphisms of innate immunity genes and environmental factors on the risk of noncardia gastric cancer. Cancer Res Treat (2013) 45:313-24. doi:10.4143/crt.2013.45.4.313
163. Wang X, Xue L, Yang Y, Xu L, Zhang G. TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One (2013) 8:e65731. doi:10.1371/journal.pone.0065731
164. Companioni O, Bonet C, Munoz X, Weiderpass E, Panico S, Tumino R, et al. Polymorphisms of Helicobacter pylori signaling pathway genes and gastric cancer risk in the European Prospective Investigation into Cancer-Eurgast cohort. Int J Cancer (2014) 134:92-101. doi:10.1002/ijc.28357
165. Li K, Dan Z, Hu XJ, Gesang LB, Ze YG, Bianba ZX, et al. Association of CD14/-260 polymorphism with gastric cancer risk in Highland Tibetans. World J Gastroenterol (2014) 20:2688-94. doi:10.3748/wjg.v20.i10.2688
166. Tahara T, Arisawa T, Shibata T, Hirata I, Nakano H. Association of polymorphism of TLR4 and CD14 genes with gastroduodenal diseases in Japan. Inflammopharmacology (2007) 15:124-8. doi:10.1007/s10787-006-1567-8
167. Zhao D, Sun T, Zhang X, Guo Y, Yu D, Yang M, et al. Role of CD14 promoter polymorphisms in Helicobacter pylori infection - related gastric carcinoma. Clin Cancer Res (2007) 13:2362-8. doi:10.1158/1078-0432.CCR-06-2612
168. Ohara T, Kanoh Y, Tani N, Ohdaira H, Suzuki Y, Kameyama J, et al. Single nucleotide polymorphism typing of the human toll-like receptor 4 gene at the 2-kb upstream region of the 5' untranslated region: new enclosure strategy for the risk grouping of poorly-differentiated gastric adenocarcinoma patients. Mol Med Rep (2009) 2:17-21. doi:10.3892/mmr_00000055
169. Ohara T, Morishita T, Suzuki H, Hibi T. Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int J Mol Med (2006) 18:59-63.
170. Castaño-Rodríguez N, Kaakoush NO, Pardo AL, Goh KL, Fock KM, Mitchell HM. Genetic polymorphisms in the Toll-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer. Hum Immunol (2014). doi:10.1016/j.humimm.2014.06.001
171. Yang JC, Yang HC, Shun CT, Wang TH, Chien CT, Kao JY. Catechins and sialic acid attenuate Helicobacter pylori-triggered epithelial caspase-1 activity and eradicate Helicobacter pylori infection. Evid Based Complement Alternat Med (2013) 2013:248585. doi:10.1155/2013/248585
172. Hishida A, Matsuo K, Goto Y, Naito M, Wakai K, Tajima K, et al. No associations of Toll-like receptor 2 (TLR2) -196 to -174del polymorphism with the risk of Helicobacter pylori seropositivity, gastric atrophy, and gastric cancer in Japanese. Gastric Cancer (2010) 13:251-7. doi:10.1007/s10120-010-0567-y
173. Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. PLoS One (2014) 9:e98899. doi:10.1371/journal.pone.0098899
174. Qadri Q, Rasool R, Afroze D, Naqash S, Gulzar GM, Yousuf A, et al. Study of TLR4 and IL-8 gene polymorphisms in H. pylori-induced inflammation in gastric cancer in an ethnic Kashmiri population. Immunol Invest (2013) 43:324-36. doi:10.3109/08820139.2013.854378
175. Schmidt HM, Ha DM, Taylor EF, Kovach Z, Goh KL, Fock KM, et al. Variation in human genetic polymorphisms, their association with Helicobacter pylori acquisition and gastric cancer in a multi-ethnic country. J Gastroenterol Hepatol (2011) 26:1725-32. doi:10.1111/j.1440-1746.2011.06799.x
176. Trejo-dela OA, Torres J, Perez-Rodriguez M, Camorlinga-Ponce M, Luna LF, Abdo-Francis JM, et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol (2008) 129:333-40. doi:10.1016/j.clim.2008.07.009
177. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer (2007) 7:70. doi:10.1186/1471-2407-7-70
178. Huang H, Wu J, Jin G, Zhang H, Ding Y, Hua Z, et al. A 5'-flanking region polymorphism in toll-like receptor 4 is associated with gastric cancer in a Chinese population. J Biomed Res (2010) 24:100-6. doi:10.1016/S1674-8301(10)60017-6
179. Kim EJ, Lee JR, Chung WC, Jung SH, Sung HJ, Lee YW, et al. Association between genetic polymorphisms of NOD 1 and Helicobacter pylori-induced gastric mucosal inflammation in healthy Korean population. Helicobacter (2013) 18:143-50. doi:10.1111/hel.12020
180. Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, Juozaityte E, et al. Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet (2011) 12:112. doi:10.1186/1471-2350-12-112
181. Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter (2009) 14:47-53. doi:10.1111/j.1523-5378.2009.00659.x
182. Hold GL, Rabkin CS, Gammon MD, Berry SH, Smith MG, Lissowska J, et al. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev (2009) 18:117-9. doi:10.1097/CEJ.0b013e3283101292
183. Wu MS, Cheng TY, Shun CT, Lin MT, Chen LC, Lin JT. Functional polymorphisms of CD14 and toll-like receptor 4 in Taiwanese Chinese with Helicobacter pylori-related gastric malignancies. Hepatogastroenterology (2006) 53:807-10.
184. Rigoli L, Di Bella C, Fedele F, Procopio V, Amorini M, Lo Giudice G, et al. TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. Anticancer Res (2010) 30:513-7.
185. Achyut BR, Ghoshal UC, Moorchung N, Mittal B. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol (2007) 68:901-7. doi:10.1016/j.humimm.2007.10.006
186. Fan YF, Wu YM, Liu H, Yu Y, Jiang YY, Xue YZ, et al. TLR4 polymorphisms associated with developing gastric pre-cancer lesions in a Chinese Han population. Hum Immunol (2014) 75:176-81. doi:10.1016/j.humimm.2013.11.002
187. Kato I, Canzian F, Plummer M, Franceschi S, Van Doorn LJ, Vivas J, et al. Polymorphisms in genes related to bacterial lipopolysaccharide/peptidoglycan signaling and gastric precancerous lesions in a population at high risk for gastric cancer. Dig Dis Sci (2007) 52:254-61. doi:10.1007/s10620-006-9303-1
188. Murphy G, Thornton J, Mcmanus R, Swan N, Ryan B, Hughes DJ, et al. Association of gastric disease with polymorphisms in the inflammatory-related genes IL-1B, IL-1RN, IL-10, TNF and TLR4. Eur J Gastroenterol Hepatol (2009) 21:630-5. doi:10.1097/MEG.0b013e3283140eea
189. Hofner P, Gyulai Z, Kiss ZF, Tiszai A, Tiszlavicz L, Toth G, et al. Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. Helicobacter (2007) 12:124-31. doi:10.1111/j.1523-5378.2007.00481.x
190. Cheng C, Lingyan W, Yi H, Cheng Z, Huadan Y, Xuting X, et al. Association between TLR2, MTR, MTRR, XPC, TP73, TP53 genetic polymorphisms and gastric cancer: a meta-analysis. Clin Res Hepatol Gastroenterol (2014). doi:10.1016/j.clinre.2013.12.009
191. Chen J, Hu S, Liang S, Chen Q, Yang Q, Zheng W, et al. Associations between the four toll-like receptor polymorphisms and the risk of gastric cancer: a meta-analysis. Cancer Biother Radiopharm (2013) 28:674-81. doi:10.1089/cbr.2012.1395
192. Zhao X, Liu L, Kang S, Zhang D. An updated meta-analysis about the association of Asp299Gly in Toll-like receptor 4 gene with risk of cancer. Eur J Cancer (2013) 49:2068-70. doi:10.1016/j.ejca.2013.01.031
193. Zhang K, Zhou B, Wang Y, Rao L, Zhang L. The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer (2013) 49:946-54. doi:10.1016/j.ejca.2012.09.022
194. Zou TH, Wang ZH, Fang JY. Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Tumour Biol (2013) 34:2441-50. doi:10.1007/s13277-013-0795-y
195. El-Omar EM, Ng MT, Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene (2008) 27:244-52. doi:10.1038/sj.onc.1210912
196. Sato K, Yoshimura A, Kaneko T, Ukai T, Ozaki Y, Nakamura H, et al. A single nucleotide polymorphism in 3'-untranslated region contributes to the regulation of Toll-like receptor 4 translation. J Biol Chem (2012) 287:25163-72. doi:10.1074/jbc.M111.338426
197. Liu J, Radler D, Illi S, Klucker E, Turan E, Von Mutius E, et al. TLR2 polymorphisms influence neonatal regulatory T cells depending on maternal atopy. Allergy (2011) 66:1020-9. doi:10.1111/j.1398-9995.2011.02573.x
198. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 6:345-52. doi:10.1038/ni1178
199. Rad R, Brenner L, Bauer S, Schwendy S, Layland L, Da Costa CP, et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology (2006) 131:525-37. doi:10.1053/j.gastro.2006.05.001
200. Jang TJ. The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol Res Pract (2010) 206:34-8. doi:10.1016/j.prp.2009.07.019
201. Kandulski A, Wex T, Kuester D, Peitz U, Gebert I, Roessner A, et al. Naturally occurring regulatory T cells (CD4+, CD25high, FOXP3+) in the antrum and cardia are associated with higher H. pylori colonization and increased gene expression of TGF-beta1. Helicobacter (2008) 13:295-303. doi:10.1111/j.1523-5378.2008.00612.x
202. Kindlund B, Sjoling A, Hansson M, Edebo A, Hansson LE, Sjovall H, et al. FOXP3-expressing CD4(+) T-cell numbers increase in areas of duodenal gastric metaplasia and are associated to CD4(+) T-cell aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. Helicobacter (2009) 14:192-201. doi:10.1111/j.1523-5378.2009.00673.x
203. Enarsson K, Lundgren A, Kindlund B, Hermansson M, Roncador G, Banham AH, et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol (2006) 121:358-68. doi:10.1016/j.clim.2006.07.002
204. Lundgren A, Stromberg E, Sjoling A, Lindholm C, Enarsson K, Edebo A, et al. Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun (2005) 73:523-31. doi:10.1128/IAI.73.1.523-531.2005
205. Junpee A, Tencomnao T, Sanprasert V, Nuchprayoon S. Association between Toll-like receptor 2 (TLR2) polymorphisms and asymptomatic bancroftian filariasis. Parasitol Res (2010) 107:807-16. doi:10.1007/s00436-010-1932-9
206. Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki M, et al. An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy (2004) 34:177-83. doi:10.1111/j.1365-2222.2004.01839.x
207. Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y, et al. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis (2007) 66:905-9. doi:10.1136/ard.2006.065961
208. Guiney DG, Hasegawa P, Cole SP. Helicobacter pylori preferentially induces interleukin 12 (IL-12) rather than IL-6 or IL-10 in human dendritic cells. Infect Immun (2003) 71:4163-6. doi:10.1128/IAI.71.7.4163-4166.2003
209. Mohammadi M, Nedrud J, Redline R, Lycke N, Czinn SJ. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology (1997) 113:1848-57. doi:10.1016/S0016-5085(97)70004-0
210. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol (2000) 165:1022-9. doi:10.4049/jimmunol.165.2.1022
211. Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK, et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology (1998) 114:482-92. doi:10.1016/S0016-5085(98)70531-1
212. Eaton KA, Mefford M, Thevenot T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol (2001) 166:7456-61. doi:10.4049/jimmunol.166.12.7456
213. Hafsi N, Voland P, Schwendy S, Rad R, Reindl W, Gerhard M, et al. Human dendritic cells respond to Helicobacter pylori, promoting NK cell and Th1-effector responses in vitro. J Immunol (2004) 173:1249-57. doi:10.4049/jimmunol.173.2.1249
214. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FDA. Polymorphism in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol (1999) 20:976-83. doi:10.1165/ajrcmb.20.5.3494
215. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, et al. C(-260) >T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation (1999) 99:3218-20. doi:10.1161/01.CIR.99.25.3218
216. Karhukorpi J, Yan Y, Niemela S, Valtonen J, Koistinen P, Joensuu T, et al. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol (2002) 128:326-32. doi:10.1046/j.1365-2249.2002.01837.x
217. Levan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol (2001) 167:5838-44. doi:10.4049/jimmunol.167.10.5838
218. Liang XH, Cheung W, Heng CK, Liu JJ, Li CW, Lim B, et al. CD14 promoter polymorphisms have no functional significance and are not associated with atopic phenotypes. Pharmacogenet Genomics (2006) 16:229-36. doi:10.1097/01.fpc.0000197466.14340.0f
219. Leipe DD, Koonin EV, Aravind L. STAND, a class of P-loop NTPases including animal and plant regulators of programmed cell death: multiple, complex domain architectures, unusual phyletic patterns, and evolution by horizontal gene transfer. J Mol Biol (2004) 343:1-28. doi:10.1016/j.jmb.2004.08.023
220. Bella J, Hindle KL, Mcewan PA, Lovell SC. The leucine-rich repeat structure. Cell Mol Life Sci (2008) 65:2307-33. doi:10.1007/s00018-008-8019-0
221. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ (2007) 14:10-22. doi:10.1038/sj.cdd.4402038
222. Tenthorey JL, Kofoed EM, Daugherty MD, Malik HS, Vance RE. Molecular basis for specific recognition of bacterial ligands by NAIP/NLRC4 inflammasomes. Mol Cell (2014) 54:17-29. doi:10.1016/j.molcel.2014.02.018
223. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol (2004) 5:1166-74. doi:10.1038/ni1131
224. Hutton ML, Kaparakis-Liaskos M, Turner L, Cardona A, Kwok T, Ferrero RL. Helicobacter pylori exploits cholesterol-rich microdomains for induction of NF-kappaB-dependent responses and peptidoglycan delivery in epithelial cells. Infect Immun (2010) 78:4523-31. doi:10.1128/IAI.00439-10
225. Kaparakis M, Turnbull L, Carneiro L, Firth S, Coleman HA, Parkington HC, et al. Bacterial membrane vesicles deliver peptidoglycan to NOD1 in epithelial cells. Cell Microbiol (2010) 12:372-85. doi:10.1111/j.1462-5822.2009.01404.x
226. Necchi V, Sommi P, Ricci V, Solcia E. In vivo accumulation of Helicobacter pylori products, NOD1, ubiquitinated proteins and proteasome in a novel cytoplasmic structure. PLoS One (2010) 5:e9716. doi:10.1371/journal.pone.0009716
227. Allison CC, Kufer TA, Kremmer E, Kaparakis M, Ferrero RL. Helicobacter pylori induces MAPK phosphorylation and AP-1 activation via a NOD1-dependent mechanism. J Immunol (2009) 183:8099-109. doi:10.4049/jimmunol.0900664
228. Allison CC, Ferrand J, Mcleod L, Hassan M, Kaparakis-Liaskos M, Grubman A, et al. Nucleotide oligomerization domain 1 enhances IFN-gamma signaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity. J Immunol (2013) 190:3706-15. doi:10.4049/jimmunol.1200591
229. Boonyanugomol W, Chomvarin C, Hahnvajanawong C, Sripa B, Kaparakis-Liaskos M, Ferrero RL. Helicobacter pylori cag pathogenicity island (cagPAI) involved in bacterial internalization and IL-8 induced responses via NOD1- and MyD88-dependent mechanisms in human biliary epithelial cells. PLoS One (2013) 8:e77358. doi:10.1371/journal.pone.0077358
230. Grubman A, Kaparakis M, Viala J, Allison C, Badea L, Karrar A, et al. The innate immune molecule, NOD1, regulates direct killing of Helicobacter pylori by antimicrobial peptides. Cell Microbiol (2010) 12:626-39. doi:10.1111/j.1462-5822.2009.01421.x
231. Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach W, et al. Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol (2006) 8:1188-98. doi:10.1111/j.1462-5822.2006.00701.x
232. Kim DJ, Park JH, Franchi L, Backert S, Nunez G. The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1beta production in Helicobacter pylori infected dendritic cells. Eur J Immunol (2013) 43:2650-8. doi:10.1002/eji.201243281
233. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol (2003) 4:95-104. doi:10.1038/nrm1019
234. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 430:213-8. doi:10.1038/nature02664
235. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell (2002) 10:417-26. doi:10.1016/S1097-2765(02)00599-3
236. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell (2004) 117:561-74. doi:10.1016/j.cell.2004.05.004
237. Tomita T, Jackson AM, Hida N, Hayat M, Dixon MF, Shimoyama T, et al. Expression of Interleukin-18, a Th1 cytokine, in human gastric mucosa is increased in Helicobacter pylori infection. J Infect Dis (2001) 183:620-7. doi:10.1086/318541
238. Potthoff A, Ledig S, Martin J, Jandl O, Cornberg M, Obst B, et al. Significance of the caspase family in Helicobacter pylori induced gastric epithelial apoptosis. Helicobacter (2002) 7:367-77. doi:10.1046/j.1523-5378.2002.00112.x
239. Benoit BN, Kobayashi M, Kawakubo M, Takeoka M, Sano K, Zou J, et al. Role of ASC in the mouse model of Helicobacter pylori infection. J Histochem Cytochem (2009) 57:327-38. doi:10.1369/jhc.2008.952366
240. Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD, et al. Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1beta and IL-18. J Immunol (2012) 188:3594-602. doi:10.4049/jimmunol.1103212
241. Shimada M, Ando T, Peek RM, Watanabe O, Ishiguro K, Maeda O, et al. Helicobacter pylori infection upregulates interleukin-18 production from gastric epithelial cells. Eur J Gastroenterol Hepatol (2008) 20:1144-50. doi:10.1097/MEG.0b013e32830edb15
242. Chen Y, Wang Y, Xu W, Zhang Z. Analysis on the mechanism of Helicobacter pylori-induced apoptosis in gastric cancer cell line BGC-823. Int J Mol Med (2005) 16:741-5. doi:10.3892/ijmm.16.4.741
243. Jiang J, Liu S, Luo J, Li X, Tang S, Yu M, et al. [The expressions of NLRP3 inflammasome and its downstream molecules in the mouse model of Helicobacter pylori infection]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2013) 29:785-8.
244. Jee CD, Lee HS, Bae SI, Yang HK, Lee YM, Rho MS, et al. Loss of caspase-1 gene expression in human gastric carcinomas and cell lines. Int J Oncol (2005) 26:1265-71. doi:10.3892/ijo.26.5.1265
245. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 12:860-75. doi:10.1038/nrc3380
246. Wang P, Zhang L, Jiang JM, Ma D, Tao HX, Yuan SL, et al. Association of NOD1 and NOD2 genes polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. World J Gastroenterol (2012) 18:2112-20. doi:10.3748/wjg.v18.i17.2112
247. Kara B, Akkiz H, Doran F, Bayram S, Erken E, Gumurdullu Y, et al. The significance of E266K polymorphism in the NOD1 gene on Helicobacter pylori infection: an effective force on pathogenesis? Clin Exp Med (2010) 10:107-12. doi:10.1007/s10238-009-0077-6
248. Hnatyszyn A, Szalata M, Stanczyk J, Cichy W, Slomski R. Association of c.802C >T polymorphism of NOD2/CARD15 gene with the chronic gastritis and predisposition to cancer in H. pylori infected patients. Exp Mol Pathol (2010) 88:388-93. doi:10.1016/j.yexmp.2010.03.003
249. Wex T, Ebert MP, Kropf S, Dierkes J, Schuttler K, Rocken C, et al. Gene polymorphisms of the NOD-2/CARD-15 gene and the risk of gastric cancer in Germany. Anticancer Res (2008) 28:757-62.
250. Angeletti S, Galluzzo S, Santini D, Ruzzo A, Vincenzi B, Ferraro E, et al. NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. Hum Immunol (2009) 70:729-32. doi:10.1016/j.humimm.2009.04.026
251. Liu J, He C, Xu Q, Xing C, Yuan Y. NOD2 polymorphisms associated with cancer risk: a meta-analysis. PLoS One (2014) 9:e89340. doi:10.1371/journal.pone.0089340
252. Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2009) 41:71-6. doi:10.1038/ng.285
253. Pontillo A, Vendramin A, Catamo E, Fabris A, Crovella S. The missense variation Q705K in CIAS1/NALP3/NLRP3 gene and an NLRP1 haplotype are associated with celiac disease. Am J Gastroenterol (2011) 106:539-44. doi:10.1038/ajg.2010.474
254. Pontillo A, Brandao L, Guimaraes R, Segat L, Araujo J, Crovella S. Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity (2010) 43:583-9. doi:10.3109/08916930903540432
255. Roberts RL, Topless RK, Phipps-Green AJ, Gearry RB, Barclay ML, Merriman TR. Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun (2010) 11:351-6. doi:10.1038/gene.2010.11
256. Yang SK, Kim H, Hong M, Lim J, Choi E, Ye BD, et al. Association of CARD8 with inflammatory bowel disease in Koreans. J Hum Genet (2011) 56:217-23. doi:10.1038/jhg.2010.170
257. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 307:734-8. doi:10.1126/science.1103685
258. Tatsuta T, Imaizumi T, Shimoyama T, Sawaya M, Kunikazu T, Matsumiya T, et al. Expression of melanoma differentiation associated gene 5 is increased in human gastric mucosa infected with Helicobacter pylori. J Clin Pathol (2012) 65:839-43. doi:10.1136/jclinpath-2011-200590
259. Gringhuis SI, Den Dunnen J, Litjens M, Van Der Vlist M, Geijtenbeek TB. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol (2009) 10:1081-8. doi:10.1038/ni.1778
260. Miszczyk E, Rudnicka K, Moran AP, Fol M, Kowalewicz-Kulbat M, Druszczynska M, et al. Interaction of Helicobacter pylori with C-type lectin dendritic cell-specific ICAM grabbing nonintegrin. J Biomed Biotechnol (2012) 2012:206463. doi:10.1155/2012/206463
261. Van Die I, Van Vliet SJ, Nyame AK, Cummings RD, Bank CM, Appelmelk B, et al. The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x. Glycobiology (2003) 13:471-8. doi:10.1093/glycob/cwg052
262. Bergman MP, Engering A, Smits HH, Van Vliet SJ, Van Bodegraven AA, Wirth HP, et al. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN. J Exp Med (2004) 200:979-90. doi:10.1084/jem.20041061
263. Chang LL, Wang SW, Wu IC, Yu FJ, Su YC, Chen YP, et al. Impaired dendritic cell maturation and IL-10 production following H. pylori stimulation in gastric cancer patients. Appl Microbiol Biotechnol (2012) 96:211-20. doi:10.1007/s00253-012-4034-z
264. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest (2012) 122:1082-96. doi:10.1172/JCI61029
265. Wu J, Lin K, Zeng J, Liu W, Yang F, Wang X, et al. Role of DC-SIGN in Helicobacter pylori infection of gastrointestinal cells. Front Biosci (Landmark Ed) (2014) 19:825-34. doi:10.2741/4250
266. Kutikhin AG, Yuzhalin AE. C-type lectin receptors and RIG-I-like receptors: new points on the oncogenomics map. Cancer Manag Res (2012) 4:39-53. doi:10.2147/CMAR.S28983
267. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med (2003) 197:1107-17. doi:10.1084/jem.20021787
268. Gringhuis SI, Den Dunnen J, Litjens M, Van Het Hof B, Van Kooyk Y, Geijtenbeek TB. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity (2007) 26:605-16. doi:10.1016/j.immuni.2007.03.012
269. Kankkunen P, Teirila L, Rintahaka J, Alenius H, Wolff H, Matikainen S. (1,3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J Immunol (2010) 184:6335-42. doi:10.4049/jimmunol.0903019
270. Pothlichet J, Meunier I, Davis BK, Ting JP, Skamene E, Von Messling V, et al. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog (2013) 9:e1003256. doi:10.1371/journal.ppat.1003256
271. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev (2012) 32:294-325. doi:10.1002/med.20214
272. Paul-Clark MJ, George PM, Gatheral T, Parzych K, Wright WR, Crawford D, et al. Pharmacology and therapeutic potential of pattern recognition receptors. Pharmacol Ther (2012) 135:200-15. doi:10.1016/j.pharmthera.2012.05.007
273. Gradisar H, Keber MM, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol (2007) 82:968-74. doi:10.1189/jlb.1206727
274. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) (2012) 5:205-15. doi:10.1158/1940-6207.CAPR-11-0247
275. Qu J, Hou Z, Han Q, Zhang C, Tian Z, Zhang J. Poly(I:C) exhibits an anti-cancer effect in human gastric adenocarcinoma cells which is dependent on RLRs. Int Immunopharmacol (2013) 17:814-20. doi:10.1016/j.intimp.2013.08.013